Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio.

JAMA neurology·2026
Same author

Identification and quantification of Hypocretin-1/Orexin-A 1-14 and 1-16 fragments in immunopurified cerebrospinal fluid using LC-MS: Comparison with radioimmunoassay (RIA) determinations.

Sleep medicine·2026
Same author

Breakpoints in Alzheimer's disease biomarkers and cognition across the aging spectrum: The Mayo Clinic Study of Aging.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Whole-proteome phage immunoprecipitation sequencing reveals germ cell tumor-specific immunosignature.

Nature communications·2026
Same author

Current State and Needs of Clinical Laboratories in Latin America: A Cross-Country Assessment.

The journal of applied laboratory medicine·2026
Same author

An automated plasma-based proteotyping immunoassay for APOE ε4 zygosity classification in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Bethany Schuder1, Daniel Figdore1, Joshua A Bornhorst1

  • 1Mayo Clinic, Rochester, MN, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

禁食状态影响阿尔茨海默病的血液生物标志物度,对p-tau217和NfL观察到显著差异. 需要进一步的研究来评估这些发现对阿尔茨海默病诊断的临床影响.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 生物化学 生物化学
  • 神经科学是一个神经科学.
  • 临床诊断 临床诊断 临床诊断

背景情况:

  • 阿尔茨海默病 (AD) 血液生物标志物 (BBM) 对临床试验和实践至关重要.
  • 需要标准化的协议来确保BBMs的可靠解释.
  • 关于禁食对ADBBM度的影响存在不一致的发现.

研究的目的:

  • 在禁食和非禁食条件下评估AD关键生物标志物的血度.
  • 评估分析前因素,特别是禁食对生物标志物测量的影响.
  • 为了比较禁食与非禁食的阿尔茨海默病血液生物标志物的样本采集.

主要方法:

  • 从14名健康捐赠者 (>55岁) 采集EDTA血,两周间隔.
  • 在标准化禁食 (≥12小时) 和非禁食条件下采集样本.
  • 使用Fujirebio Lumipulse G1200分析仪测量了粉样β (Aβ) 42,Aβ40,化Tau (p-tau) 181,p-tau217和神经丝光链 (NfL) 的血度.

主要成果:

  • 对于所有测试的生物标志物,在禁食和非禁食测量之间观察到中等到强烈的相关性.
  • 在p-tau217,NfL,p-tau217/Aβ42,Aβ42/Aβ40和Aβ42.0之间发现了统计学上显著的差异 (p ≤ 0.05).
  • 条件之间的平均百分比差异在p-tau217 (27%) 和p-tau217/Aβ42 (25%) 中显著.

结论:

  • 禁食状态可能导致某些阿尔茨海默病血液生物标志物度的统计学显著差异.
  • 在p-tau217和NfL等生物标志物中观察到的差异需要进一步调查.
  • 需要进行额外的研究,以确定这些与禁食相关的变异对粉样蛋白病理学个体生物标志物解释的临床影响.